Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors

Post time 2022-7-28 22:25:38

journal：Cancer Biotherapy and Radiopharmaceuticals

Authors：Swayamjeet Satapathy; Anish Bhattacharya; Ashwani Sood; Rakesh Kapoor; Rajesh Gupta; Apurva Sood; Prashant Sharma; Divya Khosla; Bhagwant Rai Mittal

Published date：2022-2-1

DOI：10.1089/cbr.2021.0053

Article link：http://dx.doi.org/10.1089/cbr.2021.0053

Article Source：Mary Ann Liebert Inc。

Remark：

Post time 2022-7-28 22:25:39

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Liebert] Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Liebert] Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Liebert] Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors